MDA-MB-436, a triple negative breast cancer (TNBC) cell line with a natural BRCA1 mutation and the highest expression of TLK1 among the CCLE cell lines (Fig. 3B), exhibited significantly higher sensitivity to olaparib than MDA-MB-468, a BRCA1-proficient TNBC cell line, in a cell survival assay (Fig. 3D and E). The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.